Schultz M - Search Results

1

Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.

Schultz M. Schultz M. Inflamm Bowel Dis. 2008 Jul;14(7):1012-8. doi: 10.1002/ibd.20377. Inflamm Bowel Dis. 2008. PMID: 18240278 Review.

2

Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases.

Schultz M, Schölmerich J, Rath HC. Schultz M, et al. Dig Dis. 2003;21(2):105-28. doi: 10.1159/000073243. Dig Dis. 2003. PMID: 14571109 Review.

3

Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis.

Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Göttl C, Dunger N, Grunwald N, Schölmerich J, Rath HC. Schultz M, et al. Clin Diagn Lab Immunol. 2004 Mar;11(2):372-8. doi: 10.1128/cdli.11.2.372-378.2004. Clin Diagn Lab Immunol. 2004. PMID: 15013990 Free PMC article.

4

Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo.

Schultz M, Watzl S, Oelschlaeger TA, Rath HC, Göttl C, Lehn N, Schölmerich J, Linde HJ. Schultz M, et al. J Microbiol Methods. 2005 Jun;61(3):389-98. doi: 10.1016/j.mimet.2005.01.007. J Microbiol Methods. 2005. PMID: 15767015

5

Rationale for probiotic treatment strategies in inflammatory bowel disease.

Schultz M, Lindström AL. Schultz M, et al. Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):337-55. doi: 10.1586/17474124.2.3.337. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072384 Review.

6

New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease.

Schultz M, Gearry R, Walmsley R, Day AS, Fraser A, Wyeth J, Barclay M, Clover G, Whiteside C. Schultz M, et al. N Z Med J. 2010 May 14;123(1314):134-44. N Z Med J. 2010. PMID: 20590012 Review. No abstract available.

7

Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities.

Tannock GW, Tiong IS, Priest P, Munro K, Taylor C, Richardson A, Schultz M. Tannock GW, et al. Among authors: schultz m. J Med Microbiol. 2011 Mar;60(Pt 3):366-370. doi: 10.1099/jmm.0.025874-0. Epub 2010 Dec 2. J Med Microbiol. 2011. PMID: 21127156 Clinical Trial.

8

Validation of the Dudley Inflammatory Bowel Symptom Questionnaire for the assessment of bowel symptoms in axial SpA: prevalence of clinically relevant bowel symptoms and association with disease activity.

Stebbings S, Jenks K, Treharne GJ, García JA, Schultz M, Highton J, Dudley-Brown S. Stebbings S, et al. Among authors: schultz m. Rheumatology (Oxford). 2012 May;51(5):858-65. doi: 10.1093/rheumatology/ker359. Epub 2011 Dec 30. Rheumatology (Oxford). 2012. PMID: 22210659

9

Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents.

Kemp R, Dunn E, Schultz M. Kemp R, et al. Among authors: schultz m. BioDrugs. 2013 Dec;27(6):585-90. doi: 10.1007/s40259-013-0045-2. BioDrugs. 2013. PMID: 23749336 Review.

10

Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.

Barclay ML, Karim S, Helms ETJ, Keating PE, Hock B, Stamp LK, Schultz M. Barclay ML, et al. Among authors: schultz m. Intern Med J. 2019 Apr;49(4):513-518. doi: 10.1111/imj.14064. Intern Med J. 2019. PMID: 30091273

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,318 results

Search Page